{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:58:49Z","timestamp":1787068729675,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010083","name":"Hunan Provincial Innovation Foundation for Postgraduate","doi-asserted-by":"publisher","award":["CX20190072"],"award-info":[{"award-number":["CX20190072"]}],"id":[{"id":"10.13039\/501100010083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province of China","doi-asserted-by":"crossref","award":["2018JJ1045"],"award-info":[{"award-number":["2018JJ1045"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Cardiovascular Association-Access fund","award":["2020-CCA-ACCESS-070"],"award-info":[{"award-number":["2020-CCA-ACCESS-070"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670420"],"award-info":[{"award-number":["81670420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81670426"],"award-info":[{"award-number":["No. 81670426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In patients with coronary artery disease (CAD), further increasing the level of high-density lipoprotein (HDL) cholesterol (HDL-C) as an add-on to statins cannot reduce cardiovascular risk. And it has been reported that HDL functional metric\u2014cholesterol efflux capacity (CEC) may be a better predictor of CAD risk than HDL-C. CEC measurement is time-consuming and not applicable in clinical settings. Thus, it is meaningful to explore an easily acquired index for evaluating CEC. Thirty-six CAD patients and sixty-one non-CAD controls were enrolled in this cross-sectional study. All CAD patients had acute coronary syndrome (ACS). CEC was measured using a [\n                    <jats:sup>3<\/jats:sup>\n                    H] cholesterol loading Raw 264.7 cell model with apolipoprotein B-depleted plasma (a surrogate for HDL). Proton nuclear magnetic resonance (NMR) spectroscopy was used to assess HDL components and subclass distribution. CEC was significantly impaired in CAD patients (11.9\u2009\u00b1\u20092.3%) compared to controls (13.0\u2009\u00b1\u20092.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.022). In control group, CEC was positively correlated with enzymatically measured HDL-C levels (r\u2009=\u20090.358,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) or with NMR-determined HDL-C levels (NMR-HDL-C, r\u2009=\u20090.416,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). However, in CAD group, there was no significant correlation between CEC and HDL-C (r\u2009=\u20090.216,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.206) or NMR-HDL-C (r\u2009=\u20090.065,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.708). Instead, we found that the level of high-sensitivity C-reactive protein (hsCRP) was inversely associated with CEC (r\u2009=\u2009\u2212\u20090.351,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.036). Multiple regression analysis showed that the hsCRP level was associated with CEC after adjusting other cardiovascular risk factors and HDL-C, although the association would not reach significance if adjusting for multiple testing. NMR spectroscopy showed that HDL particles shifted to larger ones in patients with high hsCRP levels, and this phenomenon was accompanied by decreased CEC. In patients with CAD, the level of HDL-C cannot reflect HDL function. The impaired correlation between HDL-C and CEC is possibly due to an inflammation-induced HDL subclass remodeling. These hypothesis-generating data suggest that hsCRP levels, a marker of acute inflammation, may associate with HDL dysfunction in ACS subjects. Due to the design limited to be correlative in nature, not permitting causal inference and a larger, strictly designed study is still needed.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-90638-0","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T11:32:54Z","timestamp":1622547174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaoyu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"1","key":"90638_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon, D. J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8\u201315 (1989).","journal-title":"Circulation"},{"issue":"21","key":"90638_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"90638_CR3","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"A-H Investigators","year":"2011","unstructured":"Investigators, A.-H. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255\u20132267 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"9841","key":"90638_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841), 572\u2013580 (2012).","journal-title":"Lancet"},{"issue":"6278","key":"90638_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni, P. et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351(6278), 1166\u20131171 (2016).","journal-title":"Science"},{"key":"90638_CR6","doi-asserted-by":"crossref","unstructured":"Hirata, A. et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J. Clin. Lipidol.\u00a012(3), 674\u2013684.e5 (2018).","DOI":"10.1016\/j.jacl.2018.01.014"},{"issue":"2","key":"90638_CR7","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1161\/ATVBAHA.117.310222","volume":"38","author":"Y He","year":"2018","unstructured":"He, Y., Kothari, V. & Bornfeldt, K. E. High-density lipoprotein function in cardiovascular disease and diabetes mellitus. Arterioscler Thromb Vasc Biol. 38(2), e10\u2013e16 (2018).","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"90638_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364(2), 127\u2013135 (2011).","journal-title":"N. Engl. J. Med."},{"key":"90638_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijcard.2015.03.362","volume":"187","author":"S Wu","year":"2015","unstructured":"Wu, S. et al. Impaired cholesterol efflux capacity is related to increased carotid intima media thickness in patients with end-stage renal disease. Int. J. Cardiol. 187, 456\u2013458 (2015).","journal-title":"Int. J. Cardiol."},{"issue":"25","key":"90638_CR10","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371(25), 2383\u20132393 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"90638_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen, D. et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 3(7), 507\u2013513 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"90638_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1161\/ATVBAHA.119.312645","volume":"39","author":"S Ebtehaj","year":"2019","unstructured":"Ebtehaj, S., Gruppen, E. G., Bakker, S. J. L., Dullaart, R. P. F. & Tietge, U. J. F. HDL (high-density lipoprotein) cholesterol efflux capacity is associated with incident cardiovascular disease in the general population. Arterioscler. Thromb. Vasc. Biol. 39(9), 1874\u20131883 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"90638_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.amjcard.2015.11.033","volume":"117","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Prognostic usefulness of serum cholesterol efflux capacity in patients with coronary artery disease. Am. J. Cardiol. 117(4), 508\u2013514 (2016).","journal-title":"Am. J. Cardiol."},{"issue":"25","key":"90638_CR14","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1016\/j.jacc.2018.09.080","volume":"72","author":"M Guerin","year":"2018","unstructured":"Guerin, M. et al. Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 72(25), 3259\u20133269 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"90638_CR15","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/ATVBAHA.117.309201","volume":"37","author":"AL Koekemoer","year":"2017","unstructured":"Koekemoer, A. L. et al. Large-scale analysis of determinants, stability, and heritability of high-density lipoprotein cholesterol efflux capacity. Arterioscler. Thromb. Vasc. Biol. 37(10), 1956\u20131962 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"90638_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1161\/CIRCRESAHA.114.303454","volume":"114","author":"B Shao","year":"2014","unstructured":"Shao, B. et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res. 114(11), 1733\u20131742 (2014).","journal-title":"Circ. Res."},{"issue":"2","key":"90638_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.amjcard.2013.09.006","volume":"113","author":"A Hafiane","year":"2014","unstructured":"Hafiane, A., Jabor, B., Ruel, I., Ling, J. & Genest, J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am. J. Cardiol. 113(2), 249\u2013255 (2014).","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"90638_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1194\/jlr.M059089","volume":"56","author":"T Vaisar","year":"2015","unstructured":"Vaisar, T. et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J. Lipid. Res. 56(8), 1519\u20131530 (2015).","journal-title":"J. Lipid. Res."},{"issue":"1","key":"90638_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.atherosclerosis.2008.04.004","volume":"202","author":"M Gomaraschi","year":"2009","unstructured":"Gomaraschi, M. et al. The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. Atherosclerosis 202(1), 304\u2013311 (2009).","journal-title":"Atherosclerosis"},{"issue":"9","key":"90638_CR20","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/art.38703","volume":"66","author":"CK Smith","year":"2014","unstructured":"Smith, C. K. et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. 66(9), 2532\u20132544 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"90638_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2016.01.012","volume":"246","author":"RW McGarrah","year":"2016","unstructured":"McGarrah, R. W. et al. High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis 246, 229\u2013235 (2016).","journal-title":"Atherosclerosis"},{"issue":"4","key":"90638_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/thoraxjnl-2018-212144","volume":"74","author":"L Harbaum","year":"2019","unstructured":"Harbaum, L. et al. Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax 74(4), 380\u2013389 (2019).","journal-title":"Thorax"},{"issue":"1","key":"90638_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12944-020-01311-w","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance. Lipids Health Dis. 19(1), 132 (2020).","journal-title":"Lipids Health Dis."},{"issue":"1","key":"90638_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-2275(20)41577-9","volume":"19","author":"GR Warnick","year":"1978","unstructured":"Warnick, G. R. & Albers, J. J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 19(1), 65\u201376 (1978).","journal-title":"J Lipid Res."},{"issue":"4","key":"90638_CR25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1194\/jlr.M066613","volume":"57","author":"WS Davidson","year":"2016","unstructured":"Davidson, W. S. et al. The effects of apolipoprotein B depletion on HDL subspecies composition and function. J. Lipid. Res. 57(4), 674\u2013686 (2016).","journal-title":"J. Lipid. Res."},{"issue":"8","key":"90638_CR26","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1021\/ja055336t","volume":"128","author":"G Wider","year":"2006","unstructured":"Wider, G. & Dreier, L. Measuring protein concentrations by NMR spectroscopy. J. Am. Chem. Soc. 128(8), 2571\u20132576 (2006).","journal-title":"J. Am. Chem. Soc."},{"issue":"20","key":"90638_CR27","doi-asserted-by":"publisher","first-page":"11962","DOI":"10.1021\/acs.analchem.8b02412","volume":"90","author":"B Jimenez","year":"2018","unstructured":"Jimenez, B. et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by (1)H NMR spectroscopy in a multilaboratory trial. Anal. Chem. 90(20), 11962\u201311971 (2018).","journal-title":"Anal. Chem."},{"issue":"3","key":"90638_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/01.ATV.0000155017.60171.88","volume":"25","author":"M Okazaki","year":"2005","unstructured":"Okazaki, M. et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc. Biol. 25(3), 578\u2013584 (2005).","journal-title":"Arterioscler Thromb Vasc. Biol."},{"issue":"1","key":"90638_CR29","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/s41598-017-02601-7","volume":"7","author":"M Luo","year":"2017","unstructured":"Luo, M. et al. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci. Rep. 7(1), 2312 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"90638_CR30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12933-018-0802-0","volume":"17","author":"E Gourgari","year":"2018","unstructured":"Gourgari, E. et al. Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study. Cardiovasc. Diabetol. 17(1), 158 (2018).","journal-title":"Cardiovasc. Diabetol."},{"issue":"16","key":"90638_CR31","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"90638_CR32","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/ATVBAHA.108.173815","volume":"28","author":"DQ Peng","year":"2008","unstructured":"Peng, D. Q. et al. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc. Biol. 28(11), 2063\u20132070 (2008).","journal-title":"Arterioscler Thromb Vasc. Biol."},{"issue":"2","key":"90638_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula, E. A. et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation 138(2), 131\u2013140 (2018).","journal-title":"Circulation"},{"issue":"19","key":"90638_CR34","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.jacc.2019.01.077","volume":"73","author":"P Guedeney","year":"2019","unstructured":"Guedeney, P. et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 73(19), 2401\u20132409 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10118","key":"90638_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391(10118), 319\u2013328 (2018).","journal-title":"Lancet"},{"issue":"8","key":"90638_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380(8), 752\u2013762 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"90638_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/cvr\/cvt169","volume":"100","author":"M Gomaraschi","year":"2013","unstructured":"Gomaraschi, M. et al. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc. Res. 100(1), 36\u201343 (2013).","journal-title":"Cardiovasc. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90638-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T19:42:05Z","timestamp":1725133325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90638"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90638-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"1 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11444"}}